Adeptrix

About:

Adeptrix has developed a mass spectrometry-based, high-content and high-throughput microarray platform for screening changes.

Website: https://www.adeptrix.com/

Top Investors: National Science Foundation, Bruker

Description:

cCorp is a developer and manufacturer of analytical reagents and assays that are based on the company’s proprietary platform technology termed Bead Assisted Mass Spectrometry (BAMS). BAMS™ is an innovative and powerful analytical platform that allows immunoassays to be measured by MALDI mass spectrometry for rapid, precise and sensitive target analyte detection. The BAMS platform technology is both multiplexed (capable of measuring multiple target analytes in a single assay) and high-throughput (capable of measuring hundreds to thousands of assays per day), making it amenable for a wide range of bio-analytical applications in drug development, basic research and clinical diagnostics.

Total Funding Amount:

$1.06M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Beverly, Massachusetts, United States

Founded Date:

2010-01-01

Contact Email:

inquire(AT)adeptrix.com

Founders:

Vladislav Bergo

Number of Employees:

11-50

Last Funding Date:

2021-01-06

IPO Status:

Private

Industries:

© 2025 bioDAO.ai